2-(2,2-二甲基-4-苯基-四氢-吡喃-4-基)-乙胺 | 126317-99-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-(2,2-二甲基-4-苯基-四氢-吡喃-4-基)-乙胺
• 英文名称: 2,2-dimethyl-4-phenyl-4-β-aminoethyltetrahydropyran
• 英文别名: 2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethanamine；2-(2,2-dimethyl-4-phenyl-tetrahydropyran-4-yl)ethylamine；2-(2,2-dimethyl-4-phenyloxan-4-yl)ethanamine
• CAS: 126317-99-5
• 化学式: C₁₅H₂₃NO
• 分子量: 233.354
• InChiKey: YZLPLFKCBAIVRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi

反应信息

• 作为反应物：
  描述：

  2-(2,2-二甲基-4-苯基-四氢-吡喃-4-基)-乙胺 在 potassium carbonate 、 三乙胺 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 2-(6-(2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethylamino)pyrazin-2-yl)benzonitrile
  参考文献：
  名称：

  [EN] TETRAHYDROPYRAN-4-YLETHYLAMINO- OR TETRAHYDROPYRANYL-4-ETHYLOXY-PYRIMIDINES OR -PYRIDAZINES AS ISOPRENYLCYSTEINCARBOXYMETHYL TRANSFERASE INHIBITORS
  [FR] PYRIMIDINES OU PYRIDAZINES TÉTRAHYDROPYRAN-4-YLÉTHYLAMINO- OU TÉTRAHYDROPYRANYL-4-ÉTHYLOXY UTILES COMME INHIBITEURS DE L'ISOPRÉNYL-CYSTÉINE-CARBOXY-MÉTHYL-TRANSFÉRASE

  摘要：

  化合物的结构式（I）：其中：R1选自：（i）苯基，可选择一个氟原子取代；（ii）噻吩基；（iii）呋喃基；（iv）C1-4烷基；和（v）氢；R2选自：（II），R3选自：（III），X选自NH和O；R4选自苯基，5-成员杂环基或6-成员杂环基，均可选择一个或多个取代基，所述取代基选自：甲基，甲氧基，三氟甲基，三氟甲氧基，氰基，氟原子，-OC2H4OMe和吡唑基。

  公开号：

  WO2014041349A1
• 作为产物：
  描述：

  (2,2-Dimethyl-4-phenyl-tetrahydro-pyran-4-yl)-acetic acid 在 ammonium hydroxide 、 lithium aluminium tetrahydride 、 氯化亚砜 、 formamide 作用下， 以 四氢呋喃 、 乙醇 、 苯 为溶剂， 反应 69.0h， 生成 2-(2,2-二甲基-4-苯基-四氢-吡喃-4-基)-乙胺
  参考文献：
  名称：

  Synthesis and anticonvulsant activity of substituted tetrahydropyran amides and amines

  摘要：

  DOI：

  10.1007/bf00766251

文献信息

• IDENTIFICATION OF ANTI-CANCER COMPOUNDS AND COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE AND METHODS OF TREATMENT THEREOF
  申请人：Stockwell Brent R.

  公开号：US20100022637A1

  公开（公告）日：2010-01-28

  Small molecule screening via high-throughput screening (HTS) methods was employed to identify compounds useful for treating or preventing cancer (such as compounds that enable cells to overcome E6-oncoprotein-mediated drug resistance) or neurodegenerative disorders (such as Huntington's disease, HD). Compounds were identified that potentiate the lethality of anti-tumor agents as well as rescue a disease-state lethality. These compounds are acylated secondary amines referred to herein as indoxins and revertins.

  高通量筛选（HTS）方法通过小分子筛选，用于鉴定可用于治疗或预防癌症（例如使细胞克服E6致癌蛋白介导的药物耐药性的化合物）或神经退行性疾病（例如亨廷顿病，HD）的化合物。已鉴定出可增强抗肿瘤药物的致死性并挽救疾病状态致死性的化合物。这些化合物是称为indoxins和revertins的酰化次级胺。
• Discovery and SAR of Methylated Tetrahydropyranyl Derivatives as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase (ICMT)
  作者：Weston R. Judd、Paul M. Slattum、Khanh C. Hoang、Leena Bhoite、Liisa Valppu、Glen Alberts、Brita Brown、Bruce Roth、Kirill Ostanin、Liwen Huang、Daniel Wettstein、Burt Richards、J. Adam Willardsen

  DOI：10.1021/jm200249a

  日期：2011.7.28

  A series of tetrahydropyranyl (THP) derivatives has been developed as potent inhibitors of isoprenylcysteine carboxyl methyltransferase (ICMT) for use as anticancer agents. Structural modification of the submicromolar hit compound 3 led to the potent 3-methoxy substituted analogue 27. Further SAR development around the THP ring resulted in an additional 10-fold increase in potency, exemplified by analogue 75 with an IC50 of 1.3 nM. Active and potent compounds demonstrated a dose-dependent increase in Ras cytosolic protein. Potent ICMT inhibitors also reduced cell viability in several cancer cell lines with growth inhibition (GI(50)) values ranging from 0.3 to >100 mu M. However, none of the cellular effects observed using ICMT inhibitors were as pronounced as those resulting from a farnesyltransferase inhibitor.
• ARUTYUNYAN, N. S.;GARIBYAN, K. M.;ASATRYAN, T. O.;TOSUNYAN, A. O.;AKOPYAN+, ARM. XIM. ZH., 42,(1989) N, S. 240-244
  作者：ARUTYUNYAN, N. S.、GARIBYAN, K. M.、ASATRYAN, T. O.、TOSUNYAN, A. O.、AKOPYAN+

  DOI：——

  日期：——
• ARUTYUNYAN, N. S.;AKOPYAN, L. A.;PARONIKYAN, R. G.;AKOPYAN, N. E., XIM.-FARMATS. ZH., 24,(1990) N, S. 29-31
  作者：ARUTYUNYAN, N. S.、AKOPYAN, L. A.、PARONIKYAN, R. G.、AKOPYAN, N. E.

  DOI：——

  日期：——
• [EN] IDENTIFICATION OF ANTI-CANCER COMPOUNDS AND COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE AND METHODS OF TREATMENT THEREOF<br/>[FR] IDENTIFICATION DE COMPOSES ANTICANCEREUX ET COMPOSES POUR LE TRAITEMENT DE LA MALADIE DE HUNTINGTON, ET PROCEDES DE TRAITEMENT CORRESPONDANTS
  申请人：UNIV COLUMBIA

  公开号：WO2007041341A2

  公开（公告）日：2007-04-12

  [EN] Small molecule screening via high-throughput screening (HTS) methods was employed to identify compounds useful for treating or preventing cancer (such as compounds that enable cells to overcome E6-oncoprotein-mediated drug resistance) or neurodegenerative disorders (such as Huntington's disease, HD). Compounds were identified that potentiate the lethality of anti-tumor agents as well as rescue a disease-state lethality. These compounds are acylated secondary amines referred to herein as indoxins and revertins.
  [FR] Un criblage de petites molécules via des procédés de criblage à haut rendement (HTS) est employé pour identifier des composés utilisés pour le traitement ou la prévention du cancer (tels que des composés permettant aux cellules de vaincre la résistance aux médicaments régulés par E6-oncoprotéine) ou des troubles de neurodégénérescence tels que la maladie de Huntington, HD). On a identifié des composés qui potentialisent la léthalité d'agents antitumoraux et qui sauvent une léthalité d'état pathologique. Ces composés sont des amines secondaires acylées désignées dans la description par indoxines et révertines.